Kym Whitley named one of Zepbound's first two paid brand ambassadors

Eli Lilly has named comedian and actress Kym Whitley as one of the first two paid brand ambassadors for Zepbound, its tirzepatide medication for chronic weight management ^[1]. The campaign centers on Whitley's own story of weight cycling, told through humor rather than the before-and-after photos common in weight-loss advertising ^[1].

Whitley, an Emmy-nominated performer known for comedic storytelling, worked directly with Lilly to shape the messaging so it reflected her actual experience ^[1]. Tom Nowlin, associate vice president of consumer marketing for cardiometabolic health at Lilly, said the goal was to use humor to open up a conversation that has often been shut down by stigma. "Humor is a way to relate to people," Nowlin said. "It'll help supercharge that conversation around open, honest, judgment free, stigma free support and people can get the help they need" ^[1].

The campaign also features social media influencer Nita Danielle and is built on what the industry calls a PESO strategy — paid, earned, shared and owned media ^[1]. That means Lilly is running traditional paid ads alongside influencer content and patient stories that spread organically through social sharing. According to Lilly, Whitley's story alone generated more than 140 million impressions ^[1]. The company says it plans to build on that reach with additional social media activity and community events, including participation in Obesity Week, a major medical conference on obesity ^[1].

Lilly frames the campaign around a specific message: that obesity is a chronic disease driven by biology, not a lack of willpower. "Science is saying that that's not really true," Nowlin said, referring to the common belief that obesity results from poor diet or lifestyle choices alone. "Your body's working against you. Millions of people have this disease and are stuck in a cycle of losing weight, trying the latest fad, but they end up gaining the weight back" ^[1].

Why it matters for patients

This is a marketing campaign, not new clinical information about Zepbound. No new trial data, dosing information, or side-effect findings are described in the source material. What has changed is how the drug is being talked about publicly: instead of dramatic before-and-after imagery, Lilly is using a comedian's own narrative about the frustration of losing and regaining weight ^[1].

For patients or prospective patients, that shift may make advertising feel less clinical and more like a personal story, which could shape expectations about what treatment involves. It's also worth knowing that Whitley is a paid ambassador, not an independent reviewer — her account was developed with the company as part of a promotional partnership ^[1]. The claim that obesity is a chronic disease driven by biology rather than willpower is described in the source as the company's marketing message, attributed to Lilly's own marketing executive rather than to a cited clinical study ^[1].

The campaign encourages people to talk with their own doctors about weight management rather than making treatment decisions based on advertising alone ^[1]. The source material does not include information about the price of Zepbound, insurance coverage, or the medication's safety profile, so those details are not addressed here.

What happens next

Lilly has said it intends to expand the campaign with additional social media activations and community events, including a presence at Obesity Week, a recurring medical conference ^[1]. No specific dates for these future events are given in the available sources, and further details on the campaign's next phase are not yet known.